Fundraise

Genelux raises $5.1M to fund cancer trial into Q1 2027

What's the deal? Genelux, a late clinical-stage immuno-oncology company, raised $5.1 million net by selling 2.55 million common shares through its at-the-market program in October and November. The sales lifted pro forma cash, restricted cash and investments to $15.5 million, enough to fund operations into the first quarter of 2027.

Why now? The raise buys time for Genelux's pivotal Phase 3 OnPrime/GOG-3076 trial of Olvi-Vec in platinum-resistant ovarian cancer, with topline data expected in the second half of 2026. It follows an $18.5 million net public offering in January, underscoring the company's continued reliance on equity financing.

What's the endgame? Genelux is advancing Olvi-Vec toward potential registration in ovarian cancer, where treatment options are limited. Olvi-Vec, its only clinical-stage candidate, is also being tested in two systemic lung cancer trials, with dose-escalation updates due by year-end.

By the numbers: Third-quarter net loss widened to $10.3 million from $8.0 million a year earlier. For the nine months to September 30, net loss grew 25% to $28.7 million, driven by a 35% rise in research and development spending to $19.2 million; the Phase 3 trial accounted for about 57% of that.

What could go wrong? Genelux again cited substantial doubt about its ability to continue as a going concern. It has no product revenue and no committed external funding, and the runway leaves little cushion if the trial readout or further financing slips.

The signal: The ATM sales are meaningful near-term liquidity, not a fix for Genelux's longer-term funding needs. With shares outstanding up 26% since year-end to 48.1 million and a sizeable overhang of options and warrants, dilution looms as a recurring cost of staying in the race toward a registration readout.

Read more: panabee.com, Financial Times

Image credit: "Chanelle Case Borden" by History at NIH, public domain (Public Domain Mark 1.0)

More top stories